Xilio Therapeutics, Inc.

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies to improve outcomes for people living with cancer while avoiding the systemic side effects of current treatments. Using its proprietary platform, it advances a pipeline of novel clinical- and preclinical-stage molecules designed to optimize therapeutic index by localizing anti-tumor activity within the tumor microenvironment. These therapies are intended to concentrate anti-tumor effects at tumor sites.